<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112735">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02043366</url>
  </required_header>
  <id_info>
    <org_study_id>GWang001</org_study_id>
    <nct_id>NCT02043366</nct_id>
  </id_info>
  <brief_title>Effect of Butorphanol Combined With Flurbiprofen Axetil on Preventing Hyperalgesia Induced by Remifentanil in Patients</brief_title>
  <official_title>Effect of Butorphanol Combined With Flurbiprofen Axetil on Preventing Postoperative Hyperalgesia Induced by Remifentanil in Patients Undergoing Lower Abdomimal Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University General Hospital</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose:

      To explore and compare antihyperalgesic effects of butorphanol, flurbiprofen axetil, and a
      combination of both received before anesthesia induction.

      To evaluate and examine the incidence of adverse effects and dose dependence with the
      purpose of selecting the optimum dose.

      To discover and confirm sex differences in antihyperalgesic activity of butorphanol, and
      identify whether butorphanol combined with flurbiprofen axetil can reverse sex differences.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are a dramatically increasing number of evidences that administration of the potent,
      ultra-short-acting opioid remifentanil seems to cause opioid-induced hyperalgesia (OIH) more
      frequently and predictably compared with the others, likely due to its rapid onset and
      offset. Therefore, prophylaxis of remifentanil induced hyperalgesia is indispensable to
      postoperative comfort and satisfaction.

      There is no denying the fact that OIH is related to central glutaminergic system and
      N-methyl-d-aspartate (NMDA) receptor-activation induced central sensitization.
      Prostaglandins can promote glutamate release from both astrocytes and spinal cord dorsal
      horns with subsequent activation of the NMDA receptors, and flurbiprofen axetil, as
      non-steroidal anti-inflammatory drugs (NSAIDs), not only functionally antagonizes the NMDA
      receptor activation via inhibition of prostaglandins, but also is a targeted drug which
      gathers at the site of inflammation, thus greatly enhances the analgesic effect. While
      butorphanol has both spinal analgesic and sedative functions because of predominantly
      central κ-receptor agonist activation, other advantages of butorphanol include few side
      effects, very low addiction potential, and low toxicity on account of a partial
      agonist-antagonist activity to μ-receptor. Moreover, antihyperalgesic activity of κ opioids
      at the site of inflammation and sex differences in the potency of the antinociceptive
      effects of κ opioids have been reported in various acute pain models. The following study is
      carried out to evaluate whether butorphanol combined with flurbiprofen axetil can be safely
      and effectively applied to preventing postoperative hyperalgesia induced by remifentanil in
      patients undergoing lower abdominal surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Mechanical hyperalgesia threshold and normalized area</measure>
    <time_frame>48 hours after surgery</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The test is measured by Von Frey filament at 48 hours postoperatively</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative sufentanyl consumption</measure>
    <time_frame>48 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Sufentanyl is administered by a PCA pump and cumulative consumption is recorded 48 hours postoperatively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain score (NRS)</measure>
    <time_frame>48 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The pain score at rest and after movement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of first postoperative analgesic requirement</measure>
    <time_frame>1 hour post surgery</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>First postoperative pain (NRS≥5) is initially controlled by titration of sufentanyl.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of side effects</measure>
    <time_frame>48 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Occurrence of side effects: nausea, vomiting, somnolence, dizziness, headache, shivering, pruritus, respiratory depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total dose of first postoperative analgesic requirement</measure>
    <time_frame>1 hour after surgery</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>First postoperative pain (NRS≥5) is initially controlled by titration of sufentanyl.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Pain</condition>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline is intravenously administrated before anesthesia induction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ButorphanolⅠ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Butorphanol is intravenously administrated at a dose of 20μg/ kg before anesthesia induction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ButorphanolⅡ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Butorphanol is intravenously administrated at a dose of 30μg/ kg before anesthesia induction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flurbiprofen axetilⅠ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Flurbiprofen axetil is intravenously administrated at a dose of 1.0mg/ kg before anesthesia induction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flurbiprofen axetilⅡ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Flurbiprofen axetil is intravenously administrated at a dose of 1.5mg/ kg before anesthesia induction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Butorphanol-Flurbiprofen axetilⅠ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A dose of 10μg/ kg butorphanol and a dose of 0.5mg/ kg flurbiprofen axetil are intravenously administrated before anesthesia induction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Butorphanol-Flurbiprofen axetilⅡ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A dose of 20μg/ kg butorphanol and a dose of 1.0mg/ kg flurbiprofen axetil are intravenously administrated before anesthesia induction</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <arm_group_label>Normal Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Butorphanol</intervention_name>
    <description>Butorphanol is intravenously administrated before anesthesia induction</description>
    <arm_group_label>ButorphanolⅠ</arm_group_label>
    <arm_group_label>ButorphanolⅡ</arm_group_label>
    <arm_group_label>Butorphanol-Flurbiprofen axetilⅠ</arm_group_label>
    <arm_group_label>Butorphanol-Flurbiprofen axetilⅡ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flurbiprofen axetil</intervention_name>
    <description>Flurbiprofen axetil is intravenously administrated before anesthesia induction</description>
    <arm_group_label>Flurbiprofen axetilⅠ</arm_group_label>
    <arm_group_label>Flurbiprofen axetilⅡ</arm_group_label>
    <arm_group_label>Butorphanol-Flurbiprofen axetilⅠ</arm_group_label>
    <arm_group_label>Butorphanol-Flurbiprofen axetilⅡ</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is scheduled to undergo lower abdominal surgery under a short general
             anesthesia of less than 2 hours

          2. Subject's American Society of Anesthesiologists physical status is I-II.

          3. The subject's parent/legally authorized guardian has given written informed consent
             to participate.

        Exclusion Criteria:

          1. Subject has a diagnosis of renal or liver failure.

          2. Subject has a diagnosis of Insulin dependent diabetes.

          3. Subject is allergy and contraindication to butorphanol or NSAIDs.

          4. Subject has a history of chronic pain, a history of alcohol or opioid abuse,
             pre-existing therapy with opioids, intake of any analgesic drug within 48 hours
             before surgery.

          5. Subject has any contraindication for the use of patient-controlled analgesia (PCA).

          6. Subject is pregnant or breast-feeding.

          7. Subject is obese (body mass index &gt;30kg/m2).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guolin Wang, M.D., Ph. D.</last_name>
      <phone>86-22-60362606</phone>
      <email>wang_guolin@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Haiyun Wang, M.D. ,Ph. D.</last_name>
      <phone>86-22-60361517</phone>
      <email>wanghy819@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Haiyun Wang, M.D., Ph. D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guolin Wang, M.D PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 21, 2014</lastchanged_date>
  <firstreceived_date>January 15, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tianjin Medical University General Hospital</investigator_affiliation>
    <investigator_full_name>Guolin Wang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Remifentanil</keyword>
  <keyword>Opioid-induced hyperalgesia</keyword>
  <keyword>Postoperative pain</keyword>
  <keyword>Pain Intensity</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperalgesia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Butorphanol</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Flurbiprofen</mesh_term>
    <mesh_term>Flurbiprofen axetil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
